GSTM1 and anemia (phenotype): Anemia benefits included conversion of transfusion-dependence at baseline to sustained transfusion-independence, substantive reductions in transfusion burden, and high rates of transfusion-independence, frequent elevation of Hb ≥ 1 g/dL; and fewer adverse events of anemia in the momelotinib arms of late phase clinical trials.